DCTH vs GYRE
DCTH: Delcath Systems is an interventional oncology company providing a proprietary drug/device combination for liver-directed cancer treatment. GYRE: A biopharmaceutical company combining a commercial-stage fibrosis franchise in China with a U.S.-based R&D platform for targeted protein degraders and oncology therapies.
Side-by-side fundamentals
| Metric | DCTH | GYRE | Edge |
|---|---|---|---|
| Price as of 2026-10-30 close | $14.04 | $4.56 | |
| Market cap | $487M | $508M | |
| Net margin FY2025, SEC XBRL | +3.2% | +8.5% | GYRE higher |
| Gross margin FY2025, SEC XBRL | +86.2% | +95.4% | GYRE higher |
| Operating margin FY2025, SEC XBRL | +0.8% | +9.9% | GYRE higher |
| ROE FY2025, SEC XBRL | +2.4% | +9.3% | GYRE higher |
| ROA FY2025, SEC XBRL | +2.2% | +5.9% | GYRE higher |
| Debt / equity 0 — no debt reported, balance sheet 2026-06-30 | n/a | 0.00 | |
| Revenue growth (YoY) FY2025, SEC XBRL | +129.1% | +10.2% | DCTH higher |
| Revenue CAGR (3y) SEC XBRL | +215.3% | +4.5% | DCTH higher |
| Dividend streak (yrs) SEC XBRL | 0 | 1 | GYRE higher |
| Beta as of 2026-09-03 | 1.37 | 1.39 | |
| 1-year return as of 2026-10-30 close | +49.4% | -40.5% | DCTH higher |
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-03 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-30.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.